ATP7A and colorectal carcinoma: Taken together, these results indicate that elesclomol promotes degradation of ATP7A, leading to copper retention in cells, which results in ROS accumulation and ferroptosis of CRC cells, thus exhibiting antitumour activity (Fig. 6G).